Falling harder than the market signals a risk problem. Beta analysis, sensitivity testing, and market factor correlations to diagnose and fix your portfolio's risk exposure. Understand risk exposure with comprehensive sensitivity analysis.
Ahead of its upcoming fiscal 2026 first-quarter earnings release, Regeneron Pharmaceuticals (NASDAQ: REGN) received a bullish rating update from TD Cowen, which lifted its 12-month price target 9.1% to $960 from $880 while reaffirming a Buy rating. The revision follows the U.S. FDA’s accelerated app
Regeneron Pharmaceuticals (REGN) - TD Cowen Ups Price Target Ahead of Fiscal Q1 Results, Supported by FDA Gene Therapy Approval - Preliminary Results
REGN - Stock Analysis
3693 Comments
549 Likes
1
Mendal
Elite Member
2 hours ago
Who else noticed this?
👍 158
Reply
2
Taureon
Engaged Reader
5 hours ago
Creativity paired with precision—wow!
👍 59
Reply
3
Siaire
Returning User
1 day ago
Market participants are cautiously optimistic, awaiting further economic or corporate developments.
👍 264
Reply
4
Arzola
Returning User
1 day ago
I read this and now I’m unsure about everything.
👍 162
Reply
5
Meer
New Visitor
2 days ago
Ah, what a missed chance! 😩
👍 70
Reply
© 2026 Market Analysis. All data is for informational purposes only.